Skip to main content
. 2019 Aug;31(4):641–652. doi: 10.21147/j.issn.1000-9604.2019.04.08

1.

Baseline demographics and clinical characteristics of study population

Characteristics All
(N=717)
Development cohort
(n=423)
Validation cohort
(n=294)
P**
All LN-positive LN-negative P* All LN-positive LN-negative P*
IQR, inter-quartile range; CT, computed tomography; LN, lymph node; *, P value was derived from univariable association analyses between each of clinicopahologic variables and LN status; **, P value was derived from comparison of patient characteristics between development cohort and validation cohort.
Age (year)
 Median (IQR) 61
(53, 67)
61
(54, 67)
59
(50, 65)
62
(55, 68)
0.002 61
(52, 67)
58
(52, 64)
62
(53, 69)
0.023 0.829
 >60 [n (%)] 365
(50.9)
214
(50.6)
51
(38.9)
163
(55.8)
0.001 151
(51.4)
38
(40.4)
113
(56.5)
0.010 0.839
Gender [n (%)]
 Male 425
(59.3)
258
(61.0)
79
(60.3)
179
(61.3)
0.846 167
(56.8)
59
(62.8)
108
(54.0)
0.157 0.261
 Female 292
(40.7)
165
(39.0)
52
(39.7)
113
(38.7)
127
(43.2)
35
(37.2)
92
(46.0)
Smoking history [n (%)]
 Yes 246
(34.3)
152
(35.9)
43
(32.8)
109
(37.3)
0.372 94
(32.0)
36
(38.3)
58
(29.0)
0.111 0.272
 No 471
(65.7)
271
(64.1)
88
(67.2)
183
(62.7)
200
(68.0)
58
(61.7)
142
(71.0)
Tumor diameter (cm)
 Median (IQR) 25
(18, 38)
26
(19, 37)
35
(26, 48)
23
(17, 32)
<0.0001 24
(17, 38)
34
(22, 44)
23
(14, 32)
<0.0001 0.146
 >3 [n (%)] 265
(37.0)
160
(37.8)
78
(59.5)
82
(28.1)
<0.0001 105
(35.7)
51
(54.3)
54
(27.0)
<0.0001 0.565
Tumor location [n (%)]
 Peripheral 575
(80.2)
340
(80.4)
73
(55.7)
267
(91.4)
<0.0001 235
(79.9)
63
(67.0)
172
(86.0)
<0.0001 0.883
 Central 142
(19.8)
83
(19.6)
58
(44.3)
25
(8.6)
59
(20.1)
31
(33.0)
28
(14.0)
CT-based LN status [n (%)]
 Negative 392
(54.7)
231
(54.6)
44
(33.6)
187
(64.0)
<0.0001 161
(54.8)
21
(22.3)
140
(70.0)
<0.0001 0.968
 Positive 325
(45.3)
192
(45.4)
87
(66.4)
105
(36.0)
133
(45.2)
73
(77.7)
60
(30.0)